Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.

Vaccine
Jeremy G SchenkeinMoon H Nahm

Abstract

The primary mode of prevention of adult disease from Streptococcus pneumoniae is vaccination with anti-capsular polysaccharide vaccine; however, its effects are less in the targeted older population than in young persons. Few studies have examined the mechanism behind this limited effectiveness. We have measured antibody concentrations and opsonization titers for multiple serotypes amongst both old adults and young, healthy controls. To avoid specificity problems associated with pneumococcal antibody ELISA, we absorbed the serum samples with c-polysaccharide and capsular polysaccharide of 22F type. Antibody concentrations were found to be similar for six out of the seven tested serotypes, while opsonization titers were significantly higher in six out of seven serotypes in the younger population. Antibody potency, as measured by the ratio of opsonization titer to antibody concentration, was found to be significantly higher for the younger subjects for all serotypes. We conclude that, while all ages of adults make similar concentrations of antibodies in response to pneumococcal vaccine, the effectiveness of those antibodies is significantly reduced in the older adult population.

References

Nov 21, 1991·The New England Journal of Medicine·E D ShapiroJ D Clemens
Aug 11, 1998·The Journal of Infectious Diseases·J B RubinsE N Janoff
Oct 9, 1999·The Journal of Infectious Diseases·X YuM H Nahm
Jul 11, 2003·Clinical and Diagnostic Laboratory Immunology·Catherine M WernetteMoon H Nahm
Sep 3, 2003·Scandinavian Journal of Immunology·H KohlerS V Kaveri
Jan 12, 2005·Clinical and Diagnostic Laboratory Immunology·David TarragóUNKNOWN Spanish Network Pneumococcus Study Group
Jan 20, 2006·Journal of the American Geriatrics Society·Ru-Chien ChiKathleen M Neuzil
Sep 9, 2006·Clinical and Vaccine Immunology : CVI·Robert L Burton, Moon H Nahm
Feb 24, 2007·Nature Reviews. Immunology·Kenneth Dorshkind, Encarnacion Montecino-Rodriguez

❮ Previous
Next ❯

Citations

Mar 4, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rajeka LazarusAndrew J Pollard
Dec 5, 2013·The Journal of Infectious Diseases·Daniel O'ConnorAndrew J Pollard
May 14, 2014·Current Opinion in Immunology·Gregory A PolandJames L Kirkland
Mar 12, 2010·BMC Infectious Diseases·Hyunju LeeKyung-Hyo Kim
May 3, 2011·Nature Reviews. Drug Discovery·Paul V LicciardiMimi L K Tang
Nov 26, 2009·Biogerontology·Alexander AdemokunDeborah Dunn-Walters
Sep 1, 2011·Biogerontology·Silvio BuffaGiuseppina Colonna-Romano
May 9, 2012·Seminars in Immunology·Igor KogutJohn C Cambier
Nov 4, 2011·The American Journal of Geriatric Pharmacotherapy·Elizabeth RightmierJack Brown
Dec 28, 2010·Ageing Research Reviews·Matteo BulatiGiuseppina Colonna Romano
Feb 14, 2015·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Chenghui LiGuoqing J Chen
Nov 14, 2013·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Camil Castelo-Branco, Iris Soveral
Jan 7, 2014·Experimental Gerontology·Matteo BulatiGiuseppina Colonna-Romano
May 10, 2013·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Joon Young SongMoon H Nahm
Jan 1, 2014·Mechanisms of Ageing and Development·Mònica MaijóSimon R Carding
Jun 27, 2014·The Journal of Infection·Charles Feldman, Ronald Anderson
Feb 24, 2015·Cellular Immunology·Melanie R Gubbels Bupp
Apr 21, 2017·Clinical and Vaccine Immunology : CVI·Hugh AdlerJamie Rylance
Dec 30, 2016·Clinical and Vaccine Immunology : CVI·Lea-Ann S KirkhamRuth B Thornton
Sep 19, 2019·Immunity & Ageing : I & a·Stephen N CrookeRichard B Kennedy
Nov 29, 2017·Expert Review of Vaccines·Richard Aspinall, Pierre Olivier Lang
Oct 30, 2013·Canada Communicable Disease Report = Relevé Des Maladies Transmissibles Au Canada·C Quach-ThanhUNKNOWN approved by NACI.
Apr 4, 2019·Frontiers in Immunology·Nely Rodriguez-ZhurbenkoAna M Hernandez
Oct 2, 2014·Expert Review of Vaccines·Anita S IyerMa Julie Westerink
Jun 4, 2014·Expert Review of Vaccines·Richard Aspinall, Pierre Olivier Lang
Sep 16, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·M B Nuvakhova, S A Rachin
Jun 10, 2017·Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology·C R LarattaH Vliagoftis
Nov 6, 2020·Vaccines·Rossella CianciGiovanni Gambassi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.